Death during study period · people with liver metastases
It is very uncertain whether transarterial embolisation and transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
1 finding from 1 review
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu)… changes proportion of people with disease progression compared with transarterial chemoembolisation (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found